Vinge advises Axcel in connection with the acquisition of Oral Care, a leading dental care provider in Sweden and Norway.

Founded in Stockholm, Sweden, in 1989, Oral Care pioneered Swedish mobile dental care, which entails treatment of elderly and disabled patients in their own homes, typically nursing homes. In 2015, Oral Care leveraged its leading mobile practice to establish a clinic footprint in Sweden. Since then, the company has expanded its clinic network by acquiring and integrating well-performing clinics in Sweden and Norway. Oral Care currently operates 12 clinics in Sweden and two in Norway. Furthermore, Oral Care is Sweden’s largest private provider of mobile dental care, active in seven regions in central and southern Sweden.

The acquisition is subject to approval from applicable competition authority.

Vinge’s team consisted of Christina Kokko, Johanna Wiberg, Elsie Nassar, Nando Basic and Ida Redander (M&A), Christoffer Nordin (Commercial Agreements, Regulatory and Permits), Mikael Ståhl, Linn Adelwald and Ellen Flygt (Banking and Financing), Frida Ställborn (Real Estate and Environmental), Julia Löfqvist (Compliance), Lina André (Employment), Nicklas Thorgerzon (IT and GDPR), Michael Montner and Ian Jonsson (Intellectual Property), Johan Wahlbom and Victoria Fredén (Merger filing) and Jessica Henning (Project and VDR Assistant).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026